Brivanib alaninate for cancer

被引：37

作者：

Diaz-Padilla, Ivan ^{[1
]}

Siu, Lillian L. ^{[1
]}

机构：

[1] Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada

来源：

EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2011年 / 20卷 / 04期

关键词：

angiogenesis; brivanib; colorectal cancer; dynamic contrast-enhanced magnetic resonance (DCE-MRI); hepatocellular carcinoma; GROWTH-FACTOR RECEPTOR-1; PHASE-I; DUAL INHIBITOR; DISCOVERY; VEGF; AMPLIFICATION; VALIDATION; EXPRESSION; RESISTANCE; MUTATIONS;

D O I：

10.1517/13543784.2011.565329

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Areas covered: This review provides an updated summary of preclinical and clinical experience with brivanib in cancer. Data presented in abstract form from international conferences or journal articles found with a PubMed search of published literature up to December 2010 are described in this review. Expert opinion: Brivanib appears tolerable and exhibits favorable pharmacokinetic and pharmacodynamic profiles with evidence of target inhibition in surrogate tissues. Clinical and pharmacodynamic data support an oral once daily administration at 800 mg. Brivanib shows promising activity as single agent in hepatocellular carcinoma and in combination with cetuximab in colorectal cancer. Further evaluations with cytotoxic chemotherapy and in other solid tumors are currently ongoing.

引用

页码：577 / 586

页数：10

共 54 条

[1]

[Anonymous], 1998, Investigator brochure: AIDSVAX B/B and AIDSVAX B/E vaccines

[2]

AYERS M, AACR M 2007

[3]

AYERS M, 2009, P GASTR CANC S

[4] Discovery and validation of biomarkers that respond to treatment with brivanib alaninate, a small-molecule VEGFR-2/FGFR-1 antagonist [J].

Ayers, Mark ;

Fargnoli, Joseph ;

Lewin, Anne ;

Wu, Qiuyan ;

Platero, J. Suso .

CANCER RESEARCH, 2007, 67 (14) :6899-6906

[5] Tumorigenesis and the angiogenic switch [J].

Bergers, G ;

Benjamin, LE .

NATURE REVIEWS CANCER, 2003, 3 (06) :401-410

[6] The Antiangiogenic Activity in Xenograft Models of Brivanib, a Dual Inhibitor of Vascular Endothelial Growth Factor Receptor-2 and Fibroblast Growth Factor Receptor-1 Kinases [J].

Bhide, Rajeev S. ;

Lombardo, Louis J. ;

Hunt, John T. ;

Cai, Zhen-wei ;

Barrish, Joel C. ;

Galbraith, Susan ;

Jeyaseelan, Robert, Sr. ;

Mortillo, Steven ;

Wautlet, Barri S. ;

Krishnan, Bala ;

Kukral, Daniel ;

Malone, Harold ;

Lewin, Anne C. ;

Henley, Benjamin J. ;

Fargnoli, Joseph .

MOLECULAR CANCER THERAPEUTICS, 2010, 9 (02) :369-378

[7] Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan-2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor [J].

Bhide, RS ;

Cai, ZW ;

Zhang, YZ ;

Qian, LG ;

Wei, D ;

Barbosa, S ;

Lombardo, LJ ;

Borzilleri, RM ;

Zheng, XP ;

Wu, LI ;

Barrish, JC ;

Kim, SH ;

Leavitt, K ;

Mathur, A ;

Leith, L ;

Chao, S ;

Wautlet, B ;

Mortillo, S ;

Jeyaseelan, R ;

Kukral, D ;

Hunt, JT ;

Kamath, A ;

Fura, A ;

Vyas, V ;

Marathe, P ;

D'Arienzo, C ;

Derbin, G ;

Fargnoli, J .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (07) :2143-2146

[8]

*BRIST MYERS SQUIB, ASC MULT DOS STUD BR

[9]

*BRIST MYERS SQUIB, 1 LIN HEP CELL CARC

[10]

*BRIST MYERS SQUIB, PHAS 1 2 COMB IR ERB

← 1 2 3 4 5 6 →